


AMENDMENTS TO AND LISTING OF CLAIMS

1. (Currently amended) A compound of formula I




I

wherein

~~R_a is H[.]] or C₁₋₄-alkyl, or C₁₋₄alkyl substituted by OH, NH₂, NHG₁₋₄alkyl or N(di-C₁₋₄alkyl)₂;~~

one of R_b, R_c, R_d and R_e is halogen, C₁₋₄-alkoxy, or C₁₋₄-alkyl, and the other three substituents are H; or R_b, R_c, R_d and R_e are all H; and

R is a radical of formula (a)



(a)

wherein

R₁ is -(CH₂)_n-NR₃R₄, wherein

each of R₃ and R₄, independently, is H or C₁₋₄-alkyl; or R₃ and R₄ form together with the nitrogen atom to which they are bound a heterocyclic residue;

n is 0, 1 or 2; and

R₂ is H, halogen, C₁₋₄-alkyl, CF₃, OH, SH, NH₂, or NO₂, C₁₋₄alkoxy, C₁₋₄alkylthio,

NHG₁₋₄alkyl, N(di-C₁₋₄alkyl)₂ or CN;

or a salt thereof.

2. (Currently amended) A compound according to Claim 1, wherein R_a is H or methyl; one of R_b, R_c, R_d and R_e is methyl or ethyl and the other three substituents are H; or R_b, R_c, R_d and R_e are all H; R₂ is H, Cl, methyl or NO₂; n is 1; and each of R₃ and R₄, independently, is H, methyl, ethyl or *i*-propyl; or R₃ and R₄ form together with the nitrogen atom to which they are bound a heterocyclic residue, or a salt thereof.

3. (Currently amended) A compound according to Claim 1, which is selected from 3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione; 3-(2-Chloro 6-methylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione; 3-(6-Aminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione; 3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione; 3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione; 3-(2-Chloro-6-methylaminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione; 3-(6-Aminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione; 3-(6-Aminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione; or and a salt of any thereof.


4. (Currently amended) A compound according to Claim 1, in free form or in a pharmaceutically-acceptable salt form, for use as a pharmaceutical.

5. and 6. (Canceled)

7. (Withdrawn by the Examiner)


8. (Currently amended) A pharmaceutical combination comprising a compound according to Claim 1, in free form or in a pharmaceutically-acceptable salt form, and a further agent selected from immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic, antiproliferative and anti-diabetic agents.

9. (Currently amended) A process for the production of the compound of formula I according to Claim 1, which process comprises reacting a compound of formula II



II

wherein R_a; R_b; R_c; R_d and R_e are as defined in Claim 1,
with a compound of formula III



wherein R is as defined in Claim 1 and claim 2,
and, where required, converting the resulting compound of formula I obtained in
free form to a salt form or *vice versa*, as appropriate.

10. (Withdrawn by the Examiner)